ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The majority of the CML patients in advanced stage (66%) and some in the chronic phase (5%) relapse after imatinib treatment, developing c-Abl dependent and independent mechanisms of resistance [44].